Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluating medicines: let's use all the evidence.

Chris W Kelman1, Sallie-Anne Pearson, Richard O Day

  • 1National Centre for Epidemiology and Population Health and ANU Medical School, Australian National University, Canberra, ACT, Australia. chris.kelman@anu.edu.au

The Medical Journal of Australia
|March 30, 2007
PubMed
Summary

Australia

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.

Clinical pharmacology and therapeutics·2026
Same author

Efficacy and Safety of Anti-nerve Growth Factor Monoclonal Antibodies in Managing Chronic Musculoskeletal Pain: A Systematic Review with Network Meta-analysis.

Drugs·2026
Same author

Recent Medicare rebates for key pharmacogenomic tests: advancing equitable access to prevent serious drug reactions.

Internal medicine journal·2026
Same author

Ending routine opioid use for acute non-specific back pain.

The American journal of emergency medicine·2026
Same author

Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses.

Drugs·2026
Same author

Formaldehyde is released from cyanoacrylate adhesives used in venous occlusion systems.

Phlebology·2026

Area of Science:

  • Pharmacovigilance and Drug Regulation
  • Health Informatics
  • Public Health Policy

Background:

  • Current drug regulatory systems are outdated, relying on premarket evaluation and post-market adverse event reporting.
  • Existing systems fail to utilize comprehensive, real-world data from long-term medicine use in chronic conditions.
  • Routinely collected data on medicine use is increasingly available and of high quality in some nations.

Purpose of the Study:

  • To propose an expanded and integrated medicines regulation system for Australia.
  • To enhance drug safety monitoring by leveraging routinely collected data and information technology.
  • To establish a novel surveillance system that complements existing regulatory frameworks.

Main Methods:

  • Proposal for an integrated regulatory system based on a surveillance model.

Related Experiment Videos

  • Utilization of high-quality, routinely collected data on medicine use.
  • Leveraging information technology for improved safety monitoring.

    • Main Results:

    • The proposed system enhances safety monitoring by integrating real-world data.
    • It complements existing drug evaluation processes, improving comprehensive evidence assessment.
    • Australia is identified as a suitable location to pilot this advanced regulatory model.

    Conclusions:

    • An expanded, integrated medicines regulation system is necessary to address limitations of current models.
    • Leveraging routinely collected data and technology can significantly improve drug safety surveillance.
    • Piloting such a system in Australia offers a unique opportunity to advance global drug regulation practices.